Graeme Sloan – Managing Director – Kali Metals (ASX:KM1) is a portfolio of assets that represents one of the largest and most prospective exploration packages across Australia’s world leading hard-rock lithium fields.
Copyright 2024 – Finance News Network
22 May 2020 - Novonix Limited (ASX:NVX) Managing Director Philip St Baker talks about the company's breakthrough dry particle microgranulation (DPMG) method for reducing waste in the manufacture of anode and cathode materials for lithium-ion batteries, restarting of operations in North America and outlook for 2H20.
01 Mar 2021 - RooLife Group Limited (ASX:RLG) CEO Bryan Carr talks about taking global brands into the Chinese market, targeting consumers directly via a range of platforms and e-commerce solutions.
07 Jul 2021 - Knosys Limited (ASX:KNO Managing Director John Thompson provides an overview of the recent acquisition of LIBERO, a leading library management software business.
17 May 2023 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses the company's letter of intent with Liberty Lithium, the advantages of the project, the difference between brine and hard rock lithium, and the timeline ahead.
21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
31 07 2024 - Amy Dickinson - Event Manager - Equity Events is a Brisbane based company which specialises in organising investment events for the mining, energy, exploration and industrial sectors.
10 June 2020 - Lepidico Limited (ASX:LPD) Managing Director, Joe Walsh provides an update on the company's plans to transition its Phase 1 Project to development following the recent completion of a Definitive Feasibility Study for the redevelopment of two mines in Namibia and a chemical conversion plant in Abu Dhabi that employs Lepidico’s proprietary process technologies.
22 Nov 2022 - Radiopharmaceutical Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.